Safe use of contrast media in myasthenia gravis: systematic review and updated European Society of Urogenital Radiology Contrast Media Safety Committee guidelines.
Remy W F GeenenGiles RoditiMarie-France BellinMichele BertolottoTorkel BrismarJean-Michel CorreasIlona A DekkersGertraud Heinz-PeerAndreas H MahnkenAart J van der MolenCarlo C QuattrocchiAlexander RadbuchPeter ReimerMaria SebastiàFulvio StaculLaura RomaniniOlivier Clémentnull nullPublished in: European radiology (2023)
• It is unclear whether modern contrast media can lead to increased symptoms in myasthenia gravis patients after intravenous administration. • There seems to be a small risk of increased myasthenia gravis symptoms within 24 h after intravenous administration of iodine-based contrast media, probably in less than 5% of the administrations. • Gadolinium-based contrast media are safe for patients with myasthenia gravis.
Keyphrases
- myasthenia gravis
- magnetic resonance
- systematic review
- contrast enhanced
- end stage renal disease
- high dose
- ejection fraction
- newly diagnosed
- magnetic resonance imaging
- chronic kidney disease
- low dose
- meta analyses
- randomized controlled trial
- clinical practice
- depressive symptoms
- physical activity
- deep learning
- dual energy